Overview

A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma

Status:
Not yet recruiting

Trial end date:
2025-12-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP regimen versus placebo with R-CHOP in the treatment of treatment-naïve patients with MCD subtype DLBCL.

Phase:

Phase 3

Details

Lead Sponsor:

Beijing InnoCare Pharma Tech Co., Ltd.

Treatments:

Cyclophosphamide
Doxorubicin
Prednisone
Rituximab
Vincristine